卵巢上皮性肿瘤中PCNA和P53蛋白表达的相关性研究

目的：研究卵巢上皮性肿瘤中ＰＣＮＡ和Ｐ５３蛋白表达的相关性。方法：应用免疫组化ＡＢＣ法检测了１０份正常卵巢，２１份卵巢腺瘤，１０份卵巢交界瘤，４０份卵巢癌的系列组织中ＰＣＮＡ及Ｐ５３蛋白的表达。所得结果除计算阳性率外，并用标记指数表示。结果：Ｐ５３蛋白表达阳性或阴性两组间的ＰＣＮＡ标记指数差异无显著性（Ｐ＞０．１０），Ｐ５３标记指数与ＰＣＮＡ标记指数呈直线正相关（ｒ＝０．６８２２，Ｐ＜０．００１～０．００２）。结论：Ｐ５３蛋白表达与否与细胞增殖活性间的关系不明显，对细胞增殖周期的调控还存在非Ｐ５３依赖型途径，但Ｐ５３标记指数与ＰＣＮＡ标记指数间呈显著正相关。     

增殖细胞核抗原在上皮性卵巢肿瘤中的表达及其临床病…

应用免疫组织化学方法检测了５９例上皮性卵巢肿瘤中增细胞核抗原（ＰＣＮＡ）的表达，以探讨卵巢肿瘤中ＰＣＮＡ蛋白表达的临床病理意义，结果：ＰＣＮＡ在良，恶性上皮性卵巢瘤中均有表达，但卵巢癌中ＰＣＮＡ的阳性率（８０．９％）明显高于良性卵巢瘤中的阳性率（２５％，Ｐ〈０．０１），卵巢癌中，高分化卵巢癌ＰＣＮＡ的阳性指数评分低于中，低分化卵巢癌（Ｐ〈０．００１），ＰＣＮＡ阳性指数评分与分化程度之间呈负相关，ｒ     

增殖细胞核抗原在上皮性卵巢肿瘤中的表达及其临床病理意义

应用免疫组织化学方法检测了５９例上皮性卵巢肿瘤中增殖细胞核抗原（ＰＣＮＡ）的表达，以探讨卵巢肿瘤中ＰＣＮＡ蛋白表达的临床病理意义。结果：ＰＣＮＡ在良、恶性上皮性卵巢瘤中均有表达，但卵巢癌中ＰＣＮＡ的阳性率（８０．９％）明显高于良性卵巢瘤中的阳性率（２５％，Ｐ＜０．０１）。卵巢癌中，高分化卵巢癌ＰＣＮＡ的阳性指数评分低于中、低分化卵巢癌（Ｐ＜０．００１），ＰＣＮＡ阳性指数评分与分化程度之间呈负相关，ｒｓ＝－０．５０（Ｐ＜０．０１）。Ⅰ／Ⅱ期卵巢癌ＰＣＮＡ指数阳性指数评分低于Ⅲ／Ⅳ期卵巢癌（Ｐ＜０．０５），ＰＣＮＡ阳性指数评分与临床期别之间呈正相关，ｒｓ＝０．４３（Ｐ＜０．０１）。结果提示，分化程度低、临床期别高的卵巢癌细胞增殖快，ＰＣＮＡ的检测有助于鉴别上皮性卵巢肿瘤的良、恶性，并有可能作为上皮性卵巢癌的预后指标。     

不同类型卵巢浆液性囊腺肿瘤p53抑癌基因蛋白的表达

不同类型卵巢浆液性囊腺肿瘤ｐ５３抑癌基因蛋白的表达刘节，杨淑杰本研究应用ｐ５３单克隆抗体以ＡＢＣ免疫组化技术检测ｐ５３蛋白在卵巢肿瘤组织中表达情况，以探讨其分布规律及临床意义。一、材料与方法１．标本：收集我院１９８５～１９９２年间卵巢浆液性囊腺肿瘤标...     

上皮性卵巢癌细胞凋亡、P53和Bcl-2表达及其与化疗的关系

目的：研究卵巢癌细胞凋亡、相关基因表达及其与化疗的关系。方法：选择卵巢上皮性癌３２例,行初次手术后给予以铂类为基础的联合化疗４ 疗程以上,１９ 例行二次手术。对２ 次手术标本分别作细胞凋亡原位检测和凋亡指数（ＡＩ）计数,细胞核增殖抗原（ＰＣＮＡ）、Ｐ５３和Ｂｃｌ ２ 基因表达免疫组化染色。结果：化疗有效组ＡＩ显著高于无效组（ｔ＝ ３．１６,Ｐ＜ ０．０５）,化疗前ＡＩ显著高于化疗后（ｔ＝ ２．２８,Ｐ＜ ０．０５）,高ＡＩ组（ＡＩ≥２．０）存活例数显著高于低ＡＩ组（ＡＩ＜ ２．０）（χ２ ＝ ６．４２,Ｐ＜ ０．０５）,平均生存期长于低ＡＩ组,但差异无显著性（ｔ＝ １．１３,Ｐ＞ ０．０５）,ＡＩ和ＰＣＮＡ变化无显著关系（ｔ＝ ０．６４,Ｐ＞ ０．０５）,高ＡＩ组伴有高Ｐ５３和高Ｂｃｌ ２ 表达趋势,但未达显著性水平（ｔ＝ ０．４８,Ｐ＞ ０．０５ 和ｔ＝ ０．７７,Ｐ＞ ０．０５）。结论：卵巢癌对化疗的效应与凋亡有关,高ＡＩ者敏感性较高,且预后良好,凋亡过程可能受Ｐ５３和Ｂｃｌ ２ 基因调控。ＡＩ检测可作为预测卵巢癌对化疗的效应和预后的指标。     

凝集素PNA、UEA_1、DBA和SBA表达与卵巢囊腺癌转移的关系

探讨凝集素ＰＮＡ（花生）、ＵＥＡ１（荆豆）、ＤＢＡ（双花扁豆）和ＳＢＡ（大豆）表达与卵巢囊腺瘤、癌变及临床转移的关系。结果显示ＰＮＡ、ＵＥＡ１在浆液性交界性囊腺瘤及囊腺癌中表达率明显高于在囊腺瘤中的表达（Ｐ＜０．０５）;ＤＢＡ、ＳＢＡ在交界性囊腺瘤增高显著（Ｐ＜０．０１）,但两者在浆液性囊腺癌中表达又显著下降（Ｐ＜０．０１）;ＰＮＡ在浆液性囊腺癌有盆腹腔转移组中表达率明显高于无转移组（Ｐ＜０．０１）,而ＤＢＡ随着浆、粘液性囊腺癌的转移,表达率降低（Ｐ＜０．０１）。ＰＮＡ、ＵＥＡ１、ＤＢＡ和ＳＢＡ在粘液性囊腺瘤,交界性粘液性囊腺瘤和粘液性囊腺癌中的表达率之间无显著差异（Ｐ＞０．０５）。提示凝集素ＰＮＡ、ＵＥＡ１、ＤＢＡ和ＳＢＡ表达检测在作为一种辅助卵巢囊腺癌诊断及预后判断方面有一定价值。     

卵巢浆液性和粘液性肿瘤共享结肠癌抗原决定簇

以抗结肠癌单克隆抗体ＳＣ１３Ａ为探针，应用免疫组织化学染色法，分别对６７例卵巢浆液性和４４例卵巢粘液性肿瘤组织，以及２０例正常卵巢组织中相应的抗原表达进行检测。结果：在浆液性囊腺瘤、交界性囊腺瘤和乳头状囊腺癌中ＳＣ１３Ａ抗原的表达率分别为８．０％，７１．４％和９０．０％；在粘液性囊腺瘤、交界性囊腺瘤和乳头状囊腺癌中ＳＣ１３Ａ抗原的表达率分别为２５．８％、８０．０％和８７．５％；正常卵巢组织中无３Ｃ１３Ａ抗原表达。浆液性、粘液性的交界性囊腺瘤和乳头状囊腺癌的抗原表达率，均显著高于浆液性、粘液性囊腺瘤及正常卵巢组织（Ｐ＜０．００５）。提示：浆液性和粘液性肿瘤抗原之间有内在的联系，这两类肿瘤的抗原中均共同享有与结肠癌抗原相同的抗原决定簇，这种抗原位点在恶性肿瘤中的表达明显高于良性肿瘤。     

P^21ras c—mycp53和雌孕激素受体在子宫内膜癌的表达

应用免疫组化ＬＳＡＢ法，对３２例子宫内膜癌，６例腺瘤型增生，２０例腺囊型增生组织的癌基因Ｐ＾２１ｒａｓ，ｃ－ｍｙｃ及抑癌基因ｐ５３蛋白表达进行了检测，对３２例子宫内膜癌进行了雌，孕激素受体的检测，并对子宫内膜癌组织Ｐ＾２１ｒａｓ，ｃ－ｍｙｃｐ５３过度表达与雌，孕激素受体的关系了分析，结果显示：Ｐ＾２１ｒａｓｃ－ｍｙｃｐ５３在子宫内膜癌组织中的阳性表达率分别为５９．４％，６２．５％和１８．８％，雌，     

卵巢的子宫内膜样癌临床情况及DNA倍体分析与p~(53)基因蛋白增殖细胞核抗原表达测定的研究

目的：研究卵巢的子宫内膜样癌ｐ５３基因蛋白、增殖细胞核抗原（ＰＣＮＡ）的表达与ＤＮＡ倍体分析之间的相互关系，并对其与临床分期、病理学分级与残存瘤的关系等进行分析、比较。方法：应用流式细胞技术及ｐ５３、ＰＣＮＡ单克隆抗体免疫组化技术对卵巢的子宫内膜样癌１３例进行倍体分析及基因、抗原测定。结果：ＤＮＡ异倍体率为７８％，ｐ５３基因蛋白表达率为４６％，ＰＣＮＡ表达率为９２％。ＤＮＡ倍体分析与临床Ⅱ～Ⅳ期、病理２～３级及残存瘤＞２ｃｍ者有关，异倍体阳性率分别为９０．９％、８８．８％、８７．５％，明显高于临床Ⅰ期、病理１级及无残存瘤者。ｐ５３在临床Ⅱ～Ⅳ期、病理２～３级表达率分别为６８．６％和５５．５％，均高于临床Ⅰ期及病理１级者，并对ＤＮＡ倍体水平与ｐ５３表达之间的关系进行了探讨。结论：ＤＮＡ异倍体与ｐ５３基因蛋白表达阳性可作为卵巢的子宫内膜样癌恶性程度的重要指标。     

宫颈癌新辅助化疗前后PCNA表达的研究

采用免疫组化Ｓ－Ｐ对新辅助化疗（ＮＡＣＴ）前后宫颈癌组织中增殖细胞核抗原（ＰＣＮＡ）表达进行检测,以探讨ＮＡＣＴ对肿瘤细胞增殖状态的影响。结果发现宫颈癌ＮＡＣＴ后ＰＣＮＡ积分显著低于ＮＡＣＴ前（Ｐ＜０．０５）;临床有效者ＮＡＣＴ前后ＰＣＮＡ积分有显著性差异（Ｐ＜０．０５）,而临床无效者ＮＡＣＴ前后则差异不显著（Ｐ＞０．０５）;临床有效、无效者ＮＡＣＴ前ＰＣＮＡ积分相比也无显著差异（Ｐ＞０．０５）。提示ＮＡＣＴ对宫颈癌细胞的增殖具有明显的抑制作用,ＰＣ－ＮＡ可作为恶性肿瘤药物治疗效果评价的一种重要参考指标。     

Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.

The frequent overexpression of prostate-derived Ets factor (PDEF) mRNA in ovarian cancer has been previously reported. The aim of this study was to evaluate PDEF protein expression in ovarian cancer and how this expression might vary at different stages of epithelial ovarian tumors in comparison to normal ovary. A new rabbit polyclonal antibody to PDEF was prepared, and immunohistochemistry was performed on tissue sections from 12 normal ovaries, 10 cases of benign serous cystadenoma, 17 cases of low malignant potential tumor, 19 cases of stage 1, and 15 cases of advanced stage primary epithelial (serous) ovarian carcinomas and their peritoneal metastases. Expression levels were assessed based on the percentage of positively staining cells and the intensity of staining. All 12 normal ovary and 10 benign serous cystadenoma cases were negative for PDEF expression. In contrast, 6 of 17 (35%) low malignant potential tumors, 5 of 19 (27%) stage 1, and 5 of 15 (33%) advanced stage ovarian tumors stained positive for PDEF expression. Together, these results show frequent overexpression of PDEF protein in epithelial ovarian tumors and its lack of expression in normal ovary and cystadenomas, and this supports a role for PDEF in ovarian tumorigenesis. Furthermore, these results suggest that PDEF is a potential marker and target in ovarian cancer.     

Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.

The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53. HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.     

AnnexinⅡ蛋白和p53蛋白在卵巢腺癌中的表达及意义

目的:探讨钙磷脂结合蛋白Ⅱ(AnnexinⅡ)和p53蛋白在卵巢腺癌中的表达及临床意义。方法:采用免疫组化SP法检测77例卵巢腺癌和30例卵巢腺瘤组织中AnnexinⅡ蛋白和p53蛋白的表达。结果:AnnexinⅡ蛋白阳性率在卵巢腺瘤组织中为46.67%(14/30),在卵巢腺癌组织中为80.52%(62/77),两组相比有显著性差异(P<0.05);p53蛋白阳性率在卵巢腺瘤组织中为0.0%(0/30),在卵巢腺癌组织中为70.13%(54/77),两组相比有显著性差异(P<0.05);AnnexinⅡ蛋白、p53蛋白阳性表达与卵巢腺癌的组织学分级、临床分期和淋巴结转移均有关(P<0.05)。卵巢腺癌中AnnexinⅡ蛋白、p53蛋白阳性表达呈正相关。结论:AnnexinⅡ蛋白、p53蛋白阳性表达与卵巢腺癌的发生、发展和淋巴结转移均有关,p53蛋白可促进AnnexinⅡ蛋白的表达。     

Prognostic importance of the nucleolar organizer region score in ovarian epithelial tumors

OBJECTIVE: The score of the silver-stained nucleolar organizer region (AgNOR) is frequently found to be high in malignant tumors. We studied AgNOR in ovarian epithelial tumors diagnosed in our hospital between 1993 and 1998. MATERIALS AND METHOD: In our study 67 ovarian epithelial tumors (18 cystadenoma, 16 borderline type, 34 cystadenocarcinoma) were stained using the method previously described by Crocker. One-way ANOVA and logistic regression tests were used to find the statistical relationship between grade, recurrence, mortality rates and AgNOR scores in tumors (p values of <0.05 were considered statistically significant). RESULTS: The mean AgNOR scores of 28 mucinous and 39 serous ovary tumors were calculated. The lowest AgNOR score of 1.33 was found in cystadenomas and the highest AgNOR score of 4.92 was found in serous and mucinous cystadenocarcinomas. In addition the relationship between mortality rate, recurrence and AgNOR score in carcinomas were studied. CONCLUSION: AgNOR scores in carcinomas were found to be higher than adenomas, and the highest AgNOR score was found in grade-III carcinomas. This shows that the AgNOR score can be used as a prognostic index in malignancies.     

卵巢克鲁根勃瘤p53蛋白表达的研究

分析胃肠道粘液腺癌转移至卵巢后Ｐ５３蛋白的表达。方法应用免疫组织化学ＢＳＡ法检测３２例卵的克鲁根勃瘤。结果阳性表达率４０．９％，且以３０岁以下，双侧肿瘤术后存活期短患者的高表达，有统计学意义。结论Ｐ５３蛋白作为独立因素影响卵巢克鲁根勃瘤的生物学行为患者的预后。     

Expression of epidermal growth factor receptors in benign ovarian tumors

The objective of the present study was to determine the level of EGFR expression in patients having benign ovarian tumors and in morphologically normal ovarian tissue by quantitative ligand binding assays. In a prospective study 42 patients with benign ovarian tumors and 30 with normal ovaries were included. In the group of patients expressing EGFR, those having benign tumors were 23 (64%) and the ones with normal ovaries--13 (36%). The average level of EGFR expression was the highest in the cases of teratoma adultum (110 fmol/mg), followed by mucinous (97 fmol/mg) and serous (30 fmol/mg) cystadenomas. The differences between the average levels of EGFR expression in mucinous and serous benign ovarian tumors were significant (p = 0.032), as for the remaining histological variants--statistically insignificant (p = 0.086). Mucinous cystadenomas possessed higher proliferative potential compared to serous cystadenomas.     

p53、p16与增殖细胞核抗原在卵巢恶性肿瘤中的表达及临床意义

目的:探讨p53、p16与增殖细胞核抗原（PCNA）在卵巢恶性肿瘤中的表达及临床意义。方法:采用免疫组化LSAB法检测p53、p16、PCNA在各种卵巢组织中的表达,并与多项临床参数进行分析。结果:恶性肿瘤中p53、PCNA的表达率明显高于卵巢正常组织、良性肿瘤及交界性肿瘤,p16的表达率则低于对照组（P<0.05）。p53、p16的表达与肿瘤的组织学分级、浸润、转移有不同程度的相关性（P<0.05）,而PCNA的表达则未见明显相关性（P>0.05）;3种指标均与患者预后有关,但与临床分期未见明显相关性（P>0.05）;p16、PCNA的表达均与p53的表达相关,但在前2者之间未见明显相关性（P>0.05）。结论:检测p53、p16、PCNA的表达对于辅助诊断卵巢恶性肿瘤、判断患者预后,具有重要价值。     

Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.

OBJECTIVE: To examine expression of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) together with microvessel count in endometrial cancer, and to investigate the relationship with clinicopathological and biological factors. METHODS: VEGF expression, TP expression, the microvessel count (factor VIII-related antigen positive cells), bcl-2 expression, proliferating cell nuclear antigen (PCNA) index, and p53 expression were determined in 50 resected endometrial cancer specimens, using immunohistochemistry. The relationship between VEGF and TP expression and correlation between expression and microvessel count were also given attention. These 3 factors were analyzed with regard to clinicopathological factors, bcl-2 expression, PCNA index, and p53 expression. RESULTS: Staining status of VEGF and TP was identical in 37 (74%) of 50 tumors, the correlation being statistically significant (p < 0.01). Combined analysis of VEGF and TP status showed that tumors which were VEGF-positive and/or TP-positive had a significantly higher microvessel count than did tumors which were both VEGF-negative and TP-negative (p < 0.001 and p < 0.05, respectively). TP expression correlated with bcl-2 expression, and VEGF expression inversely correlated with the PCNA index. Although clinical stage (p < 0.01), PCNA index (p < 0.01), and p53 expression (p < 0.01) significantly correlated with disease-free survival, neither VEGF/TP expression nor microvessel count contributed to prognostic estimates. CONCLUSIONS: VEGF and TP may cooperatively promote angiogenesis in endometrial cancer, but these expressions may have limited additional prognostic value.